Arvinas (NASDAQ:ARVN) Receives "Buy" Rating from HC Wainwright

Arvinas (NASDAQ:ARVN - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $81.00 target price on the stock.

Other analysts have also issued research reports about the stock. Guggenheim reissued a "buy" rating and issued a $57.00 price target on shares of Arvinas in a research report on Wednesday, February 12th. Cantor Fitzgerald restated an "overweight" rating on shares of Arvinas in a research report on Friday, February 7th. Stephens initiated coverage on Arvinas in a report on Monday, November 18th. They issued an "overweight" rating and a $55.00 price objective for the company. BMO Capital Markets reissued an "outperform" rating and set a $82.00 price objective (down from $88.00) on shares of Arvinas in a report on Wednesday, February 12th. Finally, Barclays cut their target price on Arvinas from $48.00 to $32.00 and set an "overweight" rating for the company in a research note on Monday, February 3rd. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $56.08.

Arvinas Price Performance

Shares of Arvinas stock traded down $9.07 during trading hours on Tuesday, hitting $8.49. 8,511,600 shares of the company's stock traded hands, compared to its average volume of 1,201,061. The company has a fifty day simple moving average of $18.22 and a 200-day simple moving average of $22.38. The stock has a market capitalization of $584.15 million, a price-to-earnings ratio of -3.07 and a beta of 1.95. Arvinas has a 12-month low of $7.91 and a 12-month high of $46.62.

Remove Ads

Arvinas (NASDAQ:ARVN - Get Free Report) last released its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating analysts' consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period in the previous year, the business earned ($2.53) EPS. On average, analysts forecast that Arvinas will post -3.81 EPS for the current fiscal year.

Insider Activity

In other Arvinas news, CEO John G. Houston sold 31,338 shares of the firm's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $16.72, for a total transaction of $523,971.36. Following the completion of the transaction, the chief executive officer now owns 1,157,480 shares of the company's stock, valued at approximately $19,353,065.60. This trade represents a 2.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Ian Taylor sold 9,020 shares of the company's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.71, for a total transaction of $150,724.20. Following the completion of the sale, the insider now directly owns 159,121 shares in the company, valued at $2,658,911.91. This represents a 5.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 41,572 shares of company stock worth $695,030 in the last quarter. 5.23% of the stock is owned by company insiders.

Institutional Investors Weigh In On Arvinas

Several hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its holdings in shares of Arvinas by 18.7% during the third quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company's stock valued at $57,371,000 after buying an additional 367,343 shares during the last quarter. Baker BROS. Advisors LP purchased a new stake in Arvinas during the 3rd quarter valued at $9,989,000. SG Americas Securities LLC raised its stake in shares of Arvinas by 228.8% in the fourth quarter. SG Americas Securities LLC now owns 32,424 shares of the company's stock worth $622,000 after purchasing an additional 22,564 shares during the last quarter. Wasatch Advisors LP lifted its holdings in shares of Arvinas by 58.3% during the third quarter. Wasatch Advisors LP now owns 435,943 shares of the company's stock valued at $10,737,000 after purchasing an additional 160,510 shares in the last quarter. Finally, Barclays PLC boosted its position in shares of Arvinas by 198.9% during the third quarter. Barclays PLC now owns 121,699 shares of the company's stock valued at $2,998,000 after buying an additional 80,984 shares during the last quarter. 95.19% of the stock is owned by institutional investors.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.